November 19, 2021 - The NASH Podcast - Surfing the NASH Tsunami Podcast

S2-E57 – AASLD 2021 TLMdX Wrap-up: Looking Back on an Eventful TLMdX

Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week’s just-concluded the AASDL 2021 TLMdX annual liver meeting.

November 19, 2021

S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

Fatty Liver Researcher and endocrinology key opinion leader Ken Cusi discusses the high levels of NAFLD prevalence and fibrosis among

Learn More »

S3-E101.1 - Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

Hepatology Researcher and Key Opinion Leader Stephen Harrison discussed results of his 2021 publication in the Journal of Hepatology that

Learn More »

S1-E1 – New Podcast: Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

In this Premier episode of The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide, key opinion leaders Doctors

Learn More »

Day: November 19, 2021

All Podcast Categories

S2-E57 – AASLD 2021 TLMdX Wrap-up: Looking Back on an Eventful TLMdX

Discussion Group

Join The Discussion in our LinkedIn or Facebook Discussion Groups

Join The Live Recordings

Recording for this session will take place at 3:15p Eastern US time (1900H CET, 1800H BT) on Monday.

Join The Discussion…

NASH & Diabetes Podcast and NASH Tsunami Podcast

S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

S1-E1 – New Podcast: Growing NAFLD-Diabetes Dual Prevalence Increases CVD Risk for Diabetics

S3-E34 – #ILC2022 Wrap-Up 1: NASH Drug Development Excitement!

S3-E1.2 – NAFLD Prevalence and Type 2 Diabetes in an Endocrinology Clinic: The Need for Screening and Vigilance

S3-E33 – Day 4 of ILC2022: Friendly debates about NITs and the Patient Advocate’s Perspective

S3-E32 – Days 1 — 3 of ILC 2022: The Value of FIB-4 and In-Person Meetings

S3-E1.1 – Fatty Liver Prevalence May Be Higher Than Previously Thought, Especially Among Type 2 Diabetes Patients

S3-E30.4 – Highlighting Intriguing ILC2022 Abstracts: Potential Uses of FIB-4

S3-E30.3 – Highlighting Intriguing ILC2022 Abstracts: More on NAFLD Quality of Life

S3-E30.2 – Highlighting Intriguing ILC2022 Abstracts: Elastography and the Importance of NAFLD Quality-of-Life Metrics

S3-E30.1 – Highlighting Intriguing ILC2022 Abstracts: Machine Learning Identified NASH Biomarkers and a Cost-Effectiveness Study

S3-E30 – Previewing #ILC2022: Focus on NITs and Patients